Join our daily newsletter At The Bell to receive exclusive market insights
- Medical cannabis company AusCann (AC8) has completed manufacturing and testing of a low-dose cannabinoid capsule in a commercial-sized batch
- This milestone confirms AusCann’s ability to customise its capsules to a controlled dosing for patients
- The company is now on target to release its capsules for physicians to prescribe in Australia during the first half of 2020
- AusCann’s share price has jumped 10.2 per cent today with shares currently trading for 29.8 cents apiece
Medicinal cannabis company AusCann (AC8) has completed manufacturing and testing of its proprietary hard-shell capsules in a low dose.
On December 18 2019, AusCann announced the successful manufacturing, testing and release of a commercial-sized batch of the cannabinoid-based capsules.
Once tested, the capsules were found to have met all applicable pre-defined criteria set out by the Australian Therapeutic Goods Administration (TGA), relevant international pharmacopoeial standards, and AusCann’s quality assurance and control procedures.
Today however, AusCann announced the successful manufacturing, testing and release of a low-dose presentation of the capsules at a commercial scale.
The TGA’s guidance document suggests that the general principle for medicinal cannabis dosing should be “start low go slow”.
Therefore, it is critical to provide doctors and patients with a controlled-dose formulation in different doses to enable titration (concentration) and personalised treatment.
“AusCann has set out to develop cannabinoid-based, controlled-dose capsules patient needs to enable accurate dose titration in a convenient formulation for patients and healthcare professionals,” CEO Ido Kanyon commented.
“We are providing a medical solution that offers regulated dosages and is in conformance with pharmaceutical quality conformance and regulatory requirements,” he added.
The company is now on target and progressing towards the goal of having its hard-shell capsules commercially available for physicians to prescribe in Australia in the first half of 2020.
AusCann’s share price has jumped 10.2 per cent with shares trading for 29.8 cents apiece at 2:16 pm AEDT.
